| Autor: |
Alfaro, Enrique, Casitas, Raquel, Díaz-García, Elena, García-Tovar, Sara, Galera, Raúl, Torres-Vargas, María, Fernández-Velilla, María, López-Ferna'ndez, Cristina, Añón, José M., Quintana-Díaz, Manuel, García-Río, Francisco, Cubillos-Zapata, Carolina |
| Předmět: |
|
| Zdroj: |
Frontiers in Immunology; 2024, p1-12, 12p |
| Abstrakt: |
Introduction: In post-COVID survivors, transforming growth factor-beta-1 (TGF-b1) might mediate fibroblast activation, resulting in persistent fibrosis. Methods: In this study, 82 survivors of COVID-19-associated ARDS were examined at 6- and 24-months post-ICU discharge. At 6-months, quantitative CT analysis of lung attenuation was performed and active TGF-b1 was measured in blood and exhaled breath condensate (EBC). Results: At 6-months of ICU-discharge, patients with reduced DmCO/alveolar volume ratio exhibited higher plasma and EBC levels of active TGF-b1. Plasma TGF-b1 levels were elevated in dyspneic survivors and directly related to the high-attenuation lung volume. In vitro, plasma and EBC from survivors induced profibrotic changes in human primary fibroblasts in a TGF-b receptordependent manner. Finally, at 6-months, plasma and EBC active TGF-b1 levels discriminated patients who, 24-months post-ICU-discharge, developed gas exchange impairment. Discussion: TGF-b1 pathway plays a pivotal role in the early-phase fibrotic abnormalities in COVID-19-induced ARDS survivors, with significant implications for long-term functional impairment. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
